Drug or treatment

Gecacitinib clinical trials

• 8Clinical trials
• 1New in 30 days
• 1Country

Newest trials

All recruiting trials (8)

• Gecacitinib for patients with myeloid neoplasms and myelofibrosis undergoing allogeneic stem cell transplant

  This study tests whether taking gecacitinib around the time of allogeneic stem cell transplantation is safe and helps engraftment in adults with myeloid neoplasms and myelofibrosis.

  Recruiting Phase 1/2 Ruijin Hospital · Shanghai · NCT07883382

• Gecacitinib plus pegylated interferon for polycythemia vera

  This study tests whether combining gecacitinib with pegylated interferon can help PV patients reach hematologic remission.

  Recruiting Peking Union Medical College Hospital · Beijing · NCT07445893

• First-line jaktinib plus corticosteroids for acute graft-versus-host disease

  This trial will test whether adding jaktinib to standard steroids helps adults with grade II–IV acute graft-versus-host disease after an allogeneic stem cell transplant.

  Recruiting Phase 1/2 First Affiliated Hospital of Zhejiang University · Hangzhou, Zhejiang · NCT07285889

• Gecacitinib with Corticosteroid as First‑Line Therapy for Grade II–IV Acute GVHD

  This study tests whether adding gecacitinib to standard corticosteroid therapy helps adults with newly diagnosed grade II–IV acute GVHD.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhou, Jiangsu · NCT07185633

• ZG005 plus gecacitinib (with or without bevacizumab) for advanced cervical cancer

  This trial will test whether adding the experimental antibody ZG005 to the JAK inhibitor gecacitinib, with or without bevacizumab, is safe and shows signs of benefit in adults with advanced cervical cancer.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Hangzhou, Zhejiang · NCT07080216

• Gecacitinib treatment for moderate-to-severe chronic GVHD after two or more prior therapies

  This trial will try oral gecacitinib in adults with moderate-to-severe chronic GVHD who have had at least two prior systemic treatments to see if it is safe and helps control disease.

  Recruiting Phase 1/2 Peking University First Hospital · Beijing · NCT07012304

• ZG005 plus gecacitinib for advanced non-small cell lung cancer

  This trial tests whether giving ZG005 by injection together with oral gecacitinib is safe and may help adults 18–75 with advanced non-small cell lung cancer that progressed after PD‑1/PD‑L1 therapy.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Shanghai, Shanghai Municipality · NCT06903377

• ZG005 with gecacitinib for relapsed or refractory lymphoma

  We are testing whether ZG005 given with gecacitinib is safe and helps adults whose lymphoma has come back or hasn't responded to prior treatments.

  Recruiting Phase 1/2 Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Hangzhou, Zhejiang · NCT06883526

Quick answers

How many clinical trials of Gecacitinib are recruiting right now?

8, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1/2: 6, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →